title: Non-Invasive Therapy of Peripheral Arterial Disease.
abstract: Peripheral arterial disease (PAD) is a significant cause of morbidity and mortality worldwide. Lifestyle changes, like the cessation of the use of tobacco as well as a modification of dietary and exercise habits, can be the most cost-effective interventions in patients with PAD. Smocking cessation is the most important intervention, since it increases survival in these patients. Antiplatelet therapy is an essential component in the treatment of peripheral arterial disease (PAD) of the lower extremities. In addition to delaying arterial obstructive progression, these agents are most usefull in reducing adverse cardiovascular events such as non-fatal myocardial infarction (MI), stroke and vascular death. Mainstay of treatment continues to be aspirin monotherapy (75-325mg daily). Current treatment for lower extremity PAD is directed towards the relief of symptoms and improvement in QoL. The two agents which have consistently been found to be most efficient in achieving these goals are cilostazol and naftidrofuryl oxalate. Naftidrofuryl oxalate may emerge as the most efficient and cost-effective treatment for symptom relief.
authors.forename: José M
authors.initials: JM
authors.lastname: Marcial
authors.forename: Reynerio
authors.initials: R
authors.lastname: Pérez
authors.forename: Pedro
authors.initials: P
authors.lastname: Vargas
authors.forename: Hilton
authors.initials: H
authors.lastname: Franqui-Rivera
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D000077407:Cilostazol; D002986:Clinical Trials as Topic; D018752:Diet, Fat-Restricted; D004038:Diet, Reducing; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000627:therapeutic use; D005081:Exercise Therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic; D009257:Nafronyl / Q000627:therapeutic use; D058729:Peripheral Arterial Disease / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016540:Smoking Cessation; D013777:Tetrazoles / Q000627:therapeutic use; D035703:Therapies, Investigational; D015431:Weight Loss
chemical_list: D000959:Antihypertensive Agents; D015507:Drugs, Investigational; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D009257:Nafronyl; D000077407:Cilostazol